Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation

Radiotherapy is an important treatment for cancer. The main mode of action is thought to be the irreversible damage to tumor cell DNA, but there is evidence that irradiation mobilizes tumor-specific immunity, and recent studies showed that the efficacy of high-dose radiotherapy depends on the presence of CD8+ T cells. We show in this study that the efficacy of radiotherapy given as a single, high dose (10 Gy) crucially depends on dendritic cells and CD8+ T cells, whereas CD4+ T cells or macrophages are dispensable. We show that local high-dose irradiation results in activation of tumor-associated dendritic cells that in turn support tumor-specific effector CD8+ T cells, thus identifying the mechanism that underlies radiotherapy-induced mobilization of tumor-specific immunity. We propose that in the absence of irradiation, the activation status of dendritic cells rather than the amount of tumor-derived Ag is the bottleneck, which precludes efficient anti-tumor immunity.

[1]  K. Iwamoto,et al.  Maximizing tumor immunity with fractionated radiation. , 2012, International journal of radiation oncology, biology, physics.

[2]  H. Moch,et al.  γ-Radiation Promotes Immunological Recognition of Cancer Cells through Increased Expression of Cancer-Testis Antigens In Vitro and In Vivo , 2011, PloS one.

[3]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[4]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[5]  R. Weichselbaum,et al.  The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. , 2011, Cancer research.

[6]  T. Okazaki,et al.  IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity , 2011, The Journal of Immunology.

[7]  E. Kostareli,et al.  Efficient Treg depletion induces T‐cell infiltration and rejection of large tumors , 2010, European journal of immunology.

[8]  H. Shirato,et al.  Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. , 2010, Cancer research.

[9]  Marzieh Ebrahimi,et al.  Contemporary immunotherapy of solid tumors: from tumor-associated antigens to combination treatments. , 2010, Current opinion in drug discovery & development.

[10]  Xuefang Cao.  Regulatory T cells and immune tolerance to tumors , 2010, Immunologic research.

[11]  T. Whiteside.  Immune responses to malignancies. , 2003, The Journal of allergy and clinical immunology.

[12]  C. Lawton,et al.  Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial , 2010 .

[13]  Yao-Tseng Chen,et al.  Cancer/testis (CT) antigens: Potential targets for immunotherapy , 2009, Cancer science.

[14]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[15]  Kevin M. Prise,et al.  Radiation-induced bystander signalling in cancer therapy , 2009, Nature Reviews Cancer.

[16]  G. Kuttan,et al.  Role of macrophages in tumour progression. , 2009, Immunology letters.

[17]  Anna M. Keller,et al.  Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. , 2008, Immunity.

[18]  C. Melief.  Cancer immunotherapy by dendritic cells. , 2008, Immunity.

[19]  R. Weichselbaum,et al.  An Initial Report of a Radiation Dose-Escalation Trial in Patients with One to Five Sites of Metastatic Disease , 2008, Clinical Cancer Research.

[20]  Albert C Koong,et al.  High-dose single-fraction radiotherapy: exploiting a new biology? , 2008, International journal of radiation oncology, biology, physics.

[21]  V. Bronte,et al.  Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells , 2008, Immunological reviews.

[22]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[23]  J. Talmadge,et al.  Inflammatory cell infiltration of tumors: Jekyll or Hyde , 2007, Cancer and Metastasis Reviews.

[24]  H. Yagita,et al.  Priming of CD8+ T cell responses by pathogens typically depends on CD70‐mediated interactions with dendritic cells , 2007, European journal of immunology.

[25]  R. Mittler,et al.  T cell costimulatory and inhibitory receptors as therapeutic targets for inducing anti-tumor immunity. , 2007, Current cancer drug targets.

[26]  C. Loddenkemper,et al.  Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease , 2007, The Journal of experimental medicine.

[27]  S. Demaria,et al.  Sensors of ionizing radiation effects on the immunological microenvironment of cancer , 2007, International journal of radiation biology.

[28]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[29]  M. Beyer,et al.  Regulatory T cells in cancer. , 2006, Blood.

[30]  R. Schwendener,et al.  Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach , 2006, British Journal of Cancer.

[31]  K. Camphausen,et al.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.

[32]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[33]  R. Zinkernagel,et al.  Histological analysis of CD11c‐DTR/GFP mice after in vivo depletion of dendritic cells , 2005, Clinical and experimental immunology.

[34]  Robert C. Rose,et al.  Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor1 , 2005, The Journal of Immunology.

[35]  F. Errington,et al.  Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naïve T-cell priming , 2005, British Journal of Cancer.

[36]  M. van den Broek,et al.  Priming of CTLs by Lymphocytic Choriomeningitis Virus Depends on Dendritic Cells1 , 2005, The Journal of Immunology.

[37]  C. N. Coleman,et al.  External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing , 2004, Cancer Research.

[38]  R. Brutkiewicz,et al.  Myeloid marker expression on antiviral CD8+ T cells following an acute virus infection , 2003, European journal of immunology.

[39]  P. Borrow,et al.  Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon , 2003, Nature Immunology.

[40]  Zvi Fuks,et al.  Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis , 2003, Science.

[41]  G. Kollias,et al.  Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. , 2003, Immunity.

[42]  Steffen Jung,et al.  In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. , 2002, Immunity.

[43]  K. Okumura,et al.  Involvement of CD70–CD27 interactions in the induction of experimental autoimmune encephalomyelitis , 2000, Journal of Neuroimmunology.

[44]  H. Pircher,et al.  Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. , 1998, Journal of immunology.

[45]  Lloyd J. Old,et al.  A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.

[46]  D. Jäger,et al.  Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.

[47]  R. Zinkernagel,et al.  Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection , 1997, European journal of immunology.

[48]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[49]  A. Rolink,et al.  The SCID but Not the RAG-2 Gene Product Is Required for Sμ–Sε Heavy Chain Class Switching , 1996 .

[50]  A. Rolink,et al.  The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. , 1996, Immunity.

[51]  S. Cobbold,et al.  The induction of skin graft tolerance in major histocompatibility complex‐mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti‐CD4 and anti‐CD8 antibodies , 1990, European journal of immunology.

[52]  Rolf M. Zinkernagel,et al.  Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo , 1990, Nature.

[53]  J. Bertram,et al.  Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture. , 1980, Cancer letters.

[54]  F. Schabel,et al.  Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. , 1975, Cancer research.